Medicine recalls
|
| |
| Canada: Sanofi-Aventis Avapro Product Recall |
| |
Health Canada announces that Sanofi-Aventis Canada Inc. is recalling three irbesartan products (i.e. Avapro 75mg Tablets, Avapro 150mg Tablets and Avapro 300mg Tablets) from retailers and healthcare practitioners due to the presence of impurity 5-(4-(azidomethyl)-[1,1-biphenyl]-2-yl)-1H-tetrazole above the acceptable concentration limit in affected lots. Details are as follows:
Avapro 75mg Tablets (lot no. FT00590)
Avapro 150mg Tablets (lot nos. ET04153, FT01995, FT01238)
Avapro 300mg Tablets (lot nos. FT00969, FT01225, FT01226, FT01999, FT04262)
Please refer to the following website in Health Canada for details:
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/../75851r-eng.php
In Hong Kong, the above products are not registered pharmaceutical products.
Ends/ Thursday, June 17, 2021
Issued at HKT 12:30
|
| |
